GSK to pay $2.2bn to settle Zantac lawsuits
GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of markets on Wednesday, the pharmaceuticals firm said it had reached an agreement with 10 firms who represent 93% of the Zantac (ranitidine) state court product liability cases pending against it in the US.
GSK surges 6.5% after US$2.2 billion Zantac lawsuits settlement
SHARES of British drugmaker GSK rose as much as 6.5 per cent on Thursday (Oct 10), after it agreed to pay up to US$2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old ...
GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...
Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve ...
London stocks rose in early trade on Thursday, taking their cue from an upbeat session on Wall Street, as investors eyed the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback